Fate Therapeutics (FATE) Current Deferred Revenue (2012 - 2026)

Fate Therapeutics has reported Current Deferred Revenue for 15 years, with the latest figure at $582000.0 in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 174.53% year-over-year to $582000.0; the trailing twelve-month figure through Mar 2026 stood at $582000.0 (up 174.53% YoY), and the FY2025 full-year result was $381000.0, down 3.05% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $582000.0, up from $381000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $42.2 million in Q4 2022, with the low at $5000.0 in Q3 2025.
• Historically, Current Deferred Revenue has averaged $9.4 million across 5 years, with a median of $685000.0 in 2023.
• Annual changes were most pronounced in 2025 — Current Deferred Revenue slumped 99.17% — and 2026, when it jumped 174.53%.
• Fate Therapeutics' Current Deferred Revenue stood at $42.2 million in 2022, then slumped by 98.38% to $685000.0 in 2023, then sank by 42.63% to $393000.0 in 2024, then dropped by 3.05% to $381000.0 in 2025, then soared by 52.76% to $582000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $582000.0 (Q1 2026), $381000.0 (Q4 2025), and $5000.0 (Q3 2025), per Business Quant data.